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Deterioration of GFR in IgA nephropathy as measured by 51Cr-EDTA
clearance. In 191 patients with mesangial IgA nephropathy, GFR was
determined as clearance of 51Cr-EDTA. 86 (45%) of them had subnor-
mal renal function 7.3 4.6 years after renal biopsy. The change in
GFR was followed in l53 patients with repeated determinations of
51Cr-EDTA clearance. 50.3% of the patients had a loss of more than 1.1
mi/mm/year, which we regard as pathological. The markers of progres-
sive disease were: male sex, high output of urinary protein, severe
histological lesions and presence of hypertension. Even patients lacking
these markers had a significantly increased incidence of progressive
disease. Of 93 patients, with initially normal GFR, 32% will have a
subnormal GFR within five years and 25% will develop end-stage renal
failure within 20 years. In 38 patients with six or more determinations of
51Cr-EDTA clearance, the predictive value of the first four determina-
tions was calculated. Of 26 with a decrease of more than 1.1 mI/mini
year, 13 (50%) developed subnormal GFR during follow-up, while 11 of
12 (91.7%) with a decrease of less than 1.1 ml/minlyear (P < 0.05)
remained normal. This shows that repeated determinations of GFR with
an accurate method will predict the final outcome early in the disease.
We also confirmed that single or repeated determinations of clearance
of creatinine are of little value in separating a normal UFR from a
slightly decreased one, but more reliable in detecting a markedly
reduced GFR.
It has been clearly established that the initial opinion that IgA
nephropathy (IgAN) is a disease with an unvariable good
prognosis [1—31 no longer holds true. Prolonged studies have
shown that 10 to 30% of the patients will develop end-stage
renal failure (ESRF) within 10 to 20 years [4—11]. Ten percent of
the patients treated for ESRF are estimated to have IgAN as the
cause of their renal failure (12].
In our own study of 176 patients [13], with a mean follow-up
time of 4.6 years after renal biopsy, 17 patients developed
end-stage renal failure (ESRF) during the study. This gives a
10-year renal survival of 79%.
The progress of the disease is often very slow and the patients
are young at the time of presentation. Therefore the progression
rate of these patients must be regularly followed for a consid-
erable period of time.
Severe histological lesions, proteinuria >1 g/24 hr and hyper-
tension are symptoms that require special attention. The prog-
nosis is also worse in males. Careful control of the blood
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pressure is the only way to influence the progression rate of the
renal disease. The blood pressure should probably be kept
below the limits regarded as normal for others [14, 151.
In 1983, we decided to study our patients diagnosed with
IgAN regularly with 51Cr-EDTA clearance as an accurate
method of GFR determination. As serum creatinine is a rough
method for determination of renal function, it is of no value in
differing between normal and slightly decreased GFR. An
extensive survey of this subject has been presented by Brod
(16]. The GFR may show a significant decline, with a serum
creatinine within normal limits.
Determination of creatinine clearance is the most common
method for evaluation of renal function in clinical practice. It is
often carried out as a 24 hour clearance. However, this method
is open to many uncertain factors, requires the active cooper-
ation of the patient, and varies in accuracy depending on the
level of GFR.
Clearances of inulin, DTPA and 51Cr-EDTA are the only
accurate methods for measurement of GFR. However, clear-
ances of inulin and DTPA are too complicated and expensive
for repeated determinations in a large number of patients.
The aim of the present study has been to detect early changes
of GFR with repeated determinations of 51Cr-EDTA clearance
in IgA nephropathy, which is a well defined group of patients.
These changes have been correlated to other clinical and
laboratory findings. A comparison has also been made between
the clearances of 51Cr-EDTA and creatinine, and the serum
creatinine as measures of renal function.
Methods
The definition of IgAN is that commonly accepted [1, 2]. All
191 patients included in this study have been investigated at our
outpatient department one or several times between the years
1980 and 1989. Routine examinations included blood pressure,
serum creatinine, serum immunoglobulins, 24-hour urinary
protein excretion, protein selectivity and 24 hour clearance of
creatinine. The GFR has been calculated from the plasma
disappearance of 51Cr-EDTA in patients with a GFR of more
than 30 mi/mm, and from conventional clearance in patients
with a GFR of less than 30 mi/mm [171. The investigations were
performed at the Department of Clinical Physiology at Hud-
dinge Hospital. GFR in the text is synonymous with clearance
of 51Cr-EDTA. Subnormal GFR was defined as a GFR lower
than mean —2 SD according to the nomogram of Granerus and
Aureli [181. These were (mean 2 SD): 30 years 105 26, 50
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Table 1. Patients with normal or subnormal renal function related to
different clinical and laboratory parameters
N NormalGFR Subnormal GFR
All 191 105 86
Mean age years 35.9 9.5 40.4 11.3
Males 130 57 (43.8%) 73 (56.2%)
Females 61 48 (78.7%) 13 (21.3%)
Proteinuria >1 g124 hr 97 30 (30.9%) 67 (69.1%)
Proteinuria <I g/24 hr 94 75 (79.8%) 19 (20.2%)
Hypertension 89 19 (21.3%) 70 (78.7%)
Normal BP 102 86 (84.3%) 16 (15.7%)
Histology 3 + 4 60 17 (28.3%) 43 (71.7%)
Histology 1 + 2 115 81(69.8%) 35 (30.2%)
years 98 23 and 70 years 78 24 ml/min/1.73 m2. GFR
determinations were made with an interval of 6 to 18 months.
All clearance values were corrected to a body surface area of
1.73 m2 according to Dubois and Dubois [191.
The slope of the regression line of51Cr-EDTA clearances was
calculated in 153 patients with two or more GFR determinations
and an interval between the first and the latest determination of
at least one year. This gives the annual change of GFR in
mLlmin/year. The GFR, when the patients begun to receive
active treatment of end-stage renal failure (ESRF) was defined
as 5 mi/mm/i .73 m2. Calculated from the work of Granerus and
Aurell [18] the lower limit of normal GFR (=mean — 2 SD)
decreases by 0.2 mI/year in controls <50 years of age and by 1.1
ml/min in controls >50 years of age. We have defined a decline
of >1.1 mI/year as a pathological decrease in GFR in all
patients.
In 38 patients, with six or more determinations of GFR, the
slope of the regression line for the first four investigations was
calculated. Only patients having a GFR within normal limits
during this period were included. The patients were divided into
two groups according to an annual change of GFR of more or
less than —1.1 mI/mm. The time of deterioration to subnormal
renal function was calculated from all GFR determinations. The
difference between the two groups was calculated by survival
statistics and the Log-Rank test.
In most patients, serum creatinine and clearances of creati-
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Fig. 1. The latest GFR (Clearance of 51Cr-EDTA) of all patients
plotted against age (N = 191). In patients who had progressed to ESRF
the GFR was defined as 5 mI/mm. Subnormal GFR was present in 86
patients.
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Fig. 2. Simultaneous measurements (N = 477) of GFR with clearances
of creatinine and of 51Cr-EDTA expressed in ml/min/1.73 m2 BSA.
Regression lines are calculated for 51Cr-EDTA <80 mI/mm (N = 254; R
= 0.78) and 51Cr-EDTA >80 mI/mm (N = 223; R = 0.36).
nine and 5tCr-EDTA were performed concomitantly several
times. Urine was collected for a period of 24 hours. A blood
sample for serum creatinine determination was taken at the end
of the period, after which then 51Cr-EDTA clearance was
determined. This enabled us to compare the reliability of
1/serum creatinine and clearance of creatinine against that of
51Cr-EDTA clearance.
Hypertension was defined as a blood pressure of >140 mm
Hg systolic or >90 mm Hg diastolic after 10 minutes supine rest
at two separate visits. All patients on antihypertensive treat-
ment were classified as hypertensive. The patients were divided
into two groups according to their protein excretion of more or
less than 1 g/24 hr. The histological scoring was based princi-
pally on the degree of mesangioproliferative changes (width and
cellularity) in the glomeruli, but the degree of tubular damage
and interstitial fibrosis and cellularity were evaluated as addi-
tional findings [13].
For statistical analysis, use was made of linear regression
analysis, Chi2 test, Students t-test and Actuarial Survival
Method {20], and Log Rank test.
Results
Figure 1 shows the latest value of GFR in each patient plotted
against age. Of 191 patients, four have a supernormal GFR and
86 (45.0%) have a subnormal GFR for their age. Of these, 22
have progressed to ESRF. In Table 1, the patients are divided
according to age, sex, degree of proteinuria, presence of
hypertension and severity of histological lesions. The incidence
of subnormal GFR is higher among males, patients with hyper-
tension, a high degree of proteinuria or more severe histological
lesions. The differences are significant (P < 0.001) for each
parameter.
Figure 2 shows the correlation between simultaneous deter-
minations of GFR with clearances of creatinine and 51Cr-
EDTA. The regression line shows that there is an over-estima-
tion of GFR with the clearance of creatinine, especially at
subnormal levels. The correlation is acceptable if GFR is <80
mi/mm (r = 0.78), but poor if GFR is >80 mi/mm (r = 0.36). The
correlation is similar between 1/Sr and a clearance of 51Cr-
EDTA (r = 0.84 and 0.33, respectively).
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Table 2. Changes in GFR in different subgroups of IgA nephropathy
GFR
.
mi/mm Follow-upof GFR
years
GFR change
Na
change
nd%
<—1.1
Initial Latest mi/mm/year
All 153 83 21 76 27 4.2 1.6 —1.4 6.5 77 50.3%
Males 106 80 21 71 27 4.3 1.5 —2.5 6.1 60 56.6%
Females 47 89 21 89 25 3.9 1.8 +1.0 6.9 17 36.2%
Histology 3 + 4 48 72 23 60 31 4.2 1.6 —3.4 8.6 32 66.7%
Histology 1 + 2 97 89 17 85 22 4.3 1.6 —0.4 5.0 41 42.3%
Proteinuria >3.5 g/24 hr Ii 56 30 29 29 3.6 1.7 —8.8 6.8 10 90.9%
Proteinuria >1 g124 hr 72 76 22 62 28 4.4 1.7 —3.6 7.1 49 68.1%
Proteinuria <1 g/24 hr 81 89 17 89 19 3.9 1.5 +0.5 5.2 28 34.6%
Hypertension 68 73 22 57 26 4.4 1.7 —4.0 6.6 48 70.6%
Normal BP 85 91 16 92 17 4.0 1.5 0.7 5.7 29 34.1%
Initial GFR <80 mi/mm 61 62 14 58 26 4.0 1.7 —1.6 8.0 30 49.2%
Initial GFR >80 mi/mm 92 96 12 88 21 4.3 1.6 —1.3 5.3 47 51.1%
Initial age >33 years 76 78 19 71 25 4.1 1.6 —1.5 6.3 34 44.7%
Initial age <33 years 77 88 22 81 29 4.3 1.6 —1.3 6.7 43 55.8%
Follow-up >4 years 89 85 20 75 25 5.3 1.0 —1.8 3.8 52 58.4%
Follow-up <4 years 64 79 22 78 31 2.6 0.9 —0.9 9 25 39.1%
Statistical significance:
Follow-up P < 0.02.
sex P < 0.02, histology P < 0.01, proteinuria P < 0.0001, blood pressure P < 0.0001, initial GFR NS, initial age NS,
It was possible to calculate the slope of the GFR regression
line in 153 patients (Table 2). Seventy-seven (50.3%) of them
had a decrease of more than 1.1 mI/mm/year and 32 (22.1%) a
decrease of more than 5 mI/mm/year. The incidence of patho-
logical decrease of GFR was higher among males, patients with
severe histological lesions, a high degree of proteinuria or with
hypertension. But the incidence of pathological decrease of
GFR was not negligible among females, patients with low
proteinuria, normotensive patients or patients with slight histo-
logical changes. The level of the initial GFR or the age at first
investigation did not correlate with the incidence of progressive
disease. The patients who had been followed for a longer period
(>4 years) had a greater incidence of pathological decrease of
GFR than those with shorter observation time.
Figure 3 shows the correlation between annual changes of
GFR measured by clearances of 51Cr-EDTA and 24 hour
creatinine in all patients. The correlation is poor (r 0.40). The
correlation between clearance of 51Cr-EDTA, an l/Scr (not
illustrated) is also poor (r 0.36). The correlation is better
when GFR is decreased (r 0.69).
Figure 4 presents all patients with initially normal GFR and a
known annual change of GFR (N = 93). Assuming that the
change in GFR is linear, we have calculated the time at which
their GFR will theoretically decrease to a subnormal level or
when they will progress to ESRF. Of these 93 patients, 32% will
develop a subnormal GFR within five years and 25% of them
will progress to ESRF within 20 years.
Figure 5 presents 38 patients with an initial GFR within
normal limits. Eleven of 12 (91.7%) with an annual decrease of
GFR of less than 1.1 mI/mm, had a normal GFR at follow up. By
contrast, 13 of 26 patients (50%) with an annual loss of more
than 1.1 ml/min had developed subnormal GFR at follow up.
The difference is significant, when calculated with survival
analysis and Log Rank test (P < 0.05).
Discussion
The variable course and the risk of permanent renal damage
in IgA nephropathy makes an accurate and comparably simple
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Fig. 3. The annual change in GFR as measured with clearance of
51Cr-EDTA and clearance of creatinine. The line represents the corre-
lation between these two methods.
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Fig. 4. Calculated progression from a GFR within normal limits (1) to
a subnormal GFR and (2) to ESRF with the actuarial survival method
calculated from first determination of 51Cr-EDTA clearance, The total
renal survival (3) in all patients with IgA nephropathy calculated from
time of renal biopsy is presented for comparison.
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Fig. 5. Survival statistics on 38 patients with six or more GFR deter-
minations and a GFR within normal limits in the first four. Upper line
shows the patients with initial annual decrease of less than I . I mi/mm
(N = 12) and the lower line the patients with a decrease of more than I .
mi/mm (N = 26). The calculation is presented as the percentage of
patients having normal GFR at follow-up. The difference is significant
(P < 0.05).
method for determination of renal function necessary. The
51Cr-EDTA clearance fulfills the requirements for such a
method.
GFR declines with increasing age measured as clearance of
inulin with 1 ml/min/year [21] and measured as clearance of
creatinine 0.8 mI/mm/year [22]. Our selected limit of 1.1 mI/mini
year is somewhat on the high side in the younger patients.
Serum creatinine and/or clearance of creatinine are standard
methods for estimating renal function in renal disease. We
compared these methods with clearance of 51Cr-EDTA, with
special regard to their ability to detect an early decline in GFR,
in our 191 patients with IgA nephropathy.
Our conclusion is that the determinations of serum creatinine
and clearance of creatinine do not discriminate between normal
or slightly decreased GFR, and are useless for early detection of
a progressive disease. In cases with advanced renal failure,
these methods are of greater value because they are more
reliable in following changes in renal function at these levels,
and can easily be performed more frequently. Our results
confirm those of Shemesh et al [231 who compared the clear-
ance of inulin with clearances of DTPA and creatinine in
various renal diseases. They too found an overestimation of
GFR with creatinine clearance in the low range.
The positive relation (Table 1) between subnormal GFR and
a high degree of proteinuria, presence of hypertension, male sex
and severe histological lesions is in accordance with other
investigations [4, 8, 9, 11, 24—30]. This further underlines the
predictive value of these factors. The proteinuria may be highly
variable, however, and hypertension is a late manifestation of
the disease [15]. Early measurements of GFR are therefore
more reliable for the determination of the prognosis.
The only risk factor available for intervention so far is
hypertension. We have recently shown that the treatment of
hypertension in these patients with an ACE inhibitor may retard
the deterioration rate compared with patients treated with
/3-blocking agents [31].
The percentage of patients (41 .6%) especially males (53.2%),
with subnormal GFR is high with regard to the mean age (37.5
years) and the observation time after renal biopsy (6.5 years).
The number of patients (77 of 153) with a pathological
decrease of GFR is alarming (Table 2). The markers of progres-
sive disease are again the same: male sex, severe histological
lesions, high degree of proteinuria and hypertension (Table 2).
In patients with a nephrotic range proteinuria, the loss of GFR
is especially high (8.8 ml/min/year) as borne out by general
clinical experience. Also, a longer observation time correlates
with a more rapid progression of the disease. However, this
may be due to the selection of the material, that is, in patients
with clinically benign disease, only one determination of GFR
may have been carried out so far. There is a tendency for a
higher percentage of progressive disease in the young age
group. The incidence of progressive disease is independent of
initial GFR.
According to actuarial survival statistics in Figure 4, 32% of
93 patients with an initial GFR within normal limits, will have a
subnormal GFR after five years and 25% will progress to ESRF
within 20 years.
The result shown in Figure 5 implies that the calculation of
the progression rate in IgA nephropathy from several determi-
nations of clearance of 51Cr-EDTA is valuable for early detec-
tion of progressive disease. The progression rate cannot be
detected early with determinations of serum creatinine or
clearance of creatinine.
It is important to define patients who are at risk at an early
stage in order to plan the future examinations to be carried out
on them, and the interval between the examinations. Our
results indicate that repeated determinations of GFR with
clearance 51Cr-EDTA are valuable in this respect.
The results of our investigation reported in this paper show
that almost half our patients have a deterioration of renal
function in spite of a low mean age and a short observation
time. This further emphasizes our previous conclusion [13, 15]
that IgA nephropathy is a severe disease in the long run.
Reprint requests to Sakari Rekola, M.D., Dept. of Renal Medicine
K56, Huddinge Hospital, S-14l 86 Huddinge, Sweden.
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